Inhibited the peak and sustained components of voltage-gated Na+ currents (INa)
Molecules. 2020 Jul 4;25(13):3062.
GH3 cells
3 µM
1 min
Inhibited the peak and sustained components of voltage-gated Na+ currents (INa)
Molecules. 2020 Jul 4;25(13):3062.
MDCK-MDR1 cells
20 µM
120 minutes
To assess the membrane permeability of Sesamolin, results showed high permeability coefficient (20.53 × 10–6 cm/s) and it is not a substrate of efflux transporters
Front Pharmacol. 2022 Nov 22;13:1046814.
Neuro-2a-CYP46A1 cells
20 µM
24 hours
To evaluate the effect of Sesamolin on CYP46A1 protein expression, results showed Sesamolin significantly reduced CYP46A1 protein levels by 57.1%
Front Pharmacol. 2022 Nov 22;13:1046814.
Bone marrow macrophages (BMMs)
0, 2.5, 5, 10 µM
5 days
Sesamolin inhibited RANKL-induced osteoclast formation in a dose-dependent manner
Front Pharmacol. 2021 Jun 14;12:664697.
Bone marrow macrophages (BMMs)
10 µM
Different stages (early: day 1-3, middle: day 3-5, late: day 5-7)
Sesamolin mainly inhibited osteoclast differentiation in the early and middle stages, especially in the early stage (day 1-3)
Front Pharmacol. 2021 Jun 14;12:664697.
Sesamolin/芝麻林素 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/c nude mice
Endometrial cancer xenograft model
Oral
30 mg/kg and 60 mg/kg
To assess the therapeutic effect of Sesamolin on endometrial cancer xenografts, results showed that Sesamolin significantly inhibited tumor growth without obvious toxicity.
Cell Mol Biol Lett. 2024 May 2;29(1):63
C57BL/6J mice
Ovariectomized (OVX)-induced osteoporosis model
Intraperitoneal injection
5 mg/kg
Every two days for 42 days
Sesamolin effectively reduced bone loss caused by estrogen deficiency and showed no significant toxic effects on the heart, liver, spleen, or kidney
Front Pharmacol. 2021 Jun 14;12:664697.
Mice
High-fat and high-fructose diet-induced nonalcoholic fatty liver disease model
Oral
60 mg/kg
Twice a day for 4 weeks
Sesamolin alleviates nonalcoholic fatty liver disease through modulating gut microbiota and metabolites in high-fat and high-fructose diet-fed mice. Sesamolin effectively suppressed obesity-associated metabolic disorder, attenuated hepatic steatosis and the infiltration of inflammatory cells, and decreased levels of hepatic proinflammatory cytokines.
搜索
